Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical Ltd has recently secured a radioactive material license from the New Hampshire Bureau of Public Health Protection, marking a significant operational milestone as it prepares to start U.S. manufacturing of its Alpha DaRT technology in 2026. The company enjoys a strong cash position, which supports its ongoing development efforts in the oncology therapeutics space targeting solid tumors. Despite reporting a net loss of $11.7 million, the strong prospects for Alpha DaRT to address unmet needs in cancer treatment contribute to a positive outlook for the company’s stock.

Bears say

Alpha Tau Medical recorded a net loss of $11.7 million in the third quarter of 2025, highlighting ongoing financial challenges for the company. Significant risks that may adversely impact its future performance include the potential failure of its Alpha DaRT technology in clinical trials, difficulties in securing regulatory approval within the U.S., and obstacles in achieving commercial success due to factors such as market size and competition. Additionally, the company faces potential dilution risks, which could further undermine investor confidence and stock performance.

DRTS has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 2 analysts, DRTS has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.